Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Qgenetics Co. Ltd. operates in the Biotechnology & Pharmaceuticals technology area. The company's patent portfolio currently features 1 pending office action that must be addressed. This active file is being reviewed by 1 distinct examiner, which simplifies the communication process between the patent office and the applicant. The prosecution is also limited to 1 distinct art unit, suggesting that the underlying technology is categorized within a specific pharmaceutical niche.
The busiest examiner for this portfolio is FIEBIG, RUSSELL G, who is currently managing 1 busiest examiner pending office action. As the total count of pending office actions is 1, this examiner's review will determine the immediate success of the company's patenting efforts. Practitioners should focus on the specific examination style of FIEBIG, RUSSELL G within the Biotechnology & Pharmaceuticals sector. The presence of 1 distinct examiner and 1 distinct art unit indicates that the company does not currently face the complexity of managing disparate examiner expectations across different technical units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FIEBIG, RUSSELL G | 1 | 62.6% | +25.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18285917 | SANGUISORBA OFFICINALIS LINNE EXTRACT COMPOSITION INHIBITING 3CL PROTEASE AND RDRP ACTIVITY OF SARS-COV-2 | FIEBIG, RUSSELL G | 4d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18285917 | SANGUISORBA OFFICINALIS LINNE EXTRACT COMPOSITION INHIBITING 3CL PROTEASE AND RDRP ACTIVITY OF SARS-COV-2 | FIEBIG, RUSSELL G | 4d overdue |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18285917 | SANGUISORBA OFFICINALIS LINNE EXTRACT COMPOSITION INHIBITING 3CL PROTEASE AND RDRP ACTIVITY OF SARS-COV-2 | FIEBIG, RUSSELL G | 1655 | §101§102§112 | Non-Final OA | 4d overdue | Pending | Oct 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial